Trial Profile
A Phase I Trial to Evaluate the Safety and Pharmacokinetics of Raltegravir in HIV-1-Exposed Neonates at Risk of Acquiring HIV-1 Infection
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Raltegravir (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacokinetics; Registrational
- 06 Jan 2020 Results published in the JAIDS
- 16 Dec 2019 Planned End Date changed from 30 Apr 2020 to 30 Apr 2021.
- 16 Dec 2019 Planned primary completion date changed from 31 Mar 2020 to 31 Mar 2021.